Figure 5.
Chemogenetic activation of unilateral substantia nigra (SN) drives contralateral rotation behavior
(A) Example of the top view of the Head trajectory of Marmo1 50–60 min after vehicle and deschloroclozapine (DCZ; 10 μg/kg, per os [PO]) administration and 24 hr after DCZ administration.
(B) Postural changes characterized by the positions of the Head and Body relative to the body axis. Left top: The body axis, i.e., the anterior–posterior (A–P) axis, is defined as that through the center of the Head and Body, whereas the ipsilateral-contralateral (I-C) and dorsal-ventral (D-V) axes are defined as those horizontally and vertically orthogonal to the A-P axis. Left bottom: Relative Head and Hip positions were determined every 3 s in the A–P I–C plane. Right: Scatterplots of the Head (red) and Hip (blue) positions over a 15-min period following vehicle and DCZ (PO) administration and 24 hr after DCZ administration (Marmo1).
(C) Comparison of the average horizontal Head speed (Vhor) scaled per individual with the vehicle conditions equal to 1 in animals treated with vehicle and DCZ (blue: IP; red: PO), and 24 hr after DCZ administration (post) for Marmo1 and Marmo2. (D) Comparison of the average frequency of contralateral rotation among three conditions.
(E) Representative trends of the cumulative sum of the contraversive rotation every 5 min across conditions in Marmo2. Color scale representing the time after the treatment/test start.
(F) Total number of contraversive rotations for every sliding 10-min window for IP (blue) and PO DCZ treatment (red) in Marmo2. Gray shadow represents the 95% confidence intervals of the cumulative sum of θrot under the vehicle condition.
(G) Comparison of the latency of significant behavioral changes between IP and PO DCZ treatment, which was defined as the first deviation time from the 95% confidence interval of those under the vehicle condition. Asterisks indicate a significant difference (p < 0.01, two-way ANOVA). See also Figures S1 and S2.